Sofosbuvir-Velpatasvir Successful in Hep C Regardless of Genotype

Share this content:
Sofosbuvir-Velpatasvir Successful in Hep C Regardless of Genotype
Sofosbuvir-Velpatasvir Successful in Hep C Regardless of Genotype

WEDNESDAY, Nov. 18, 2015 (HealthDay News) -- Sofosbuvir-velpatasvir is effective for hepatitis C virus (HCV), regardless of genotype, according to three studies published online Nov. 17 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Association for the Study of Liver Diseases, held from Nov. 13 to 17 in San Francisco.

Jordan J. Feld, M.D., M.P.H., from the Toronto Western Hospital Liver Centre, and colleagues conducted a phase 3 study involving patients with HCV genotypes 1, 2, 4, 5, or 6, who were randomized to receive sofosbuvir and velpatasvir or matching placebo. The researchers found that among the 624 patients receiving sofosbuvir-velpatasvir, the rate of sustained virologic response was 99 percent at 12 weeks after the end of therapy; two patients had a virologic relapse.

Michael P. Curry, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues conducted a phase 3 study involving 267 patients with HCV genotypes 1 through 6 who had decompensated cirrhosis. Participants were randomized to 12 weeks of sofosbuvir-velpatasvir or sofosbuvir-velpatasvir plus ribavirin, or to 24 weeks of sofosbuvir-velpatasvir. The researchers found that the overall sustained virologic response was 83, 94, and 86 percent, respectively, with no significant between-group differences. In a third study, Graham R. Foster, Ph.D., from the Queen Mary University of London, and colleagues found that 12 weeks of sofosbuvir-velpatasvir treatment resulted in superior rates of sustained virologic response versus sofosbuvir-ribavirin among patients with HCV genotype 2 or 3.

"These studies indicate that this drug regimen can achieve high rates of HCV cure regardless of genotype," write the authors of an accompanying editorial.

All three studies were funded by Gilead Sciences, the manufacturer of sofosbuvir-velpatasvir.

Abstract - Feld
Full Text
Abstract - Curry
Full Text
Abstract - Foster
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

E. Coli Found in Water at Tennessee Ziplining Facility

<i>E. Coli</i> Found in Water at Tennessee Ziplining ...

One visitor to the CLIMB Works Zipline Canopy Tour in Gatlinburg tested positive for norovirus and E. coli

FDA: Illnesses Tied to Fresh Crab Meat Imported From Venezuela

FDA: Illnesses Tied to Fresh Crab Meat Imported ...

Illnesses appear to be caused by Vibrio parahaemolyticus bacteria

FDA Approves First Drug to Treat Smallpox

FDA Approves First Drug to Treat Smallpox

New treatment offers additional option should smallpox ever be used as a bioweapon

is free, fast, and customized just for you!




Already a member?

Sign In Now »